256 related articles for article (PubMed ID: 15526670)
1. [Overactive bladder. New anticholinergic drug controls urinary urge].
MMW Fortschr Med; 2004 Jul; 146(27-28):51. PubMed ID: 15526670
[No Abstract] [Full Text] [Related]
2. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
Jonas U; Rackley RR
Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
[No Abstract] [Full Text] [Related]
3. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Wein AJ
J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
[No Abstract] [Full Text] [Related]
4. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
Roberts RG; Garely AD; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
[TBL] [Abstract][Full Text] [Related]
5. Tolterodine.
Nurs Times; 2006 Jun 6-12; 102(23):27. PubMed ID: 16784047
[No Abstract] [Full Text] [Related]
6. Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.
Capo' JP; Lucente V; Forero-Schwanhaeuser S; He W
Postgrad Med; 2011 Jan; 123(1):94-104. PubMed ID: 21293089
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
9. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
10. Solifenacin versus tolterodine--a head-to-head study: finally! But not final?
Staskin DR; Dmochowski RR; Wein AJ
Curr Urol Rep; 2005 Nov; 6(6):403-4. PubMed ID: 16238911
[No Abstract] [Full Text] [Related]
11. [Less disability in daily activities].
Krankenpfl J; 2005; 43(7-10):191. PubMed ID: 16515263
[No Abstract] [Full Text] [Related]
12. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
[TBL] [Abstract][Full Text] [Related]
13. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Colli E; Parazzini F; Olivieri L; Cipriani S; Bertozzi R; Meschia M; Montorsi F
Eur Urol; 2007 Aug; 52(2):525-30. PubMed ID: 17449169
[TBL] [Abstract][Full Text] [Related]
14. PHARMAC responds on tolterodine for overactive bladder.
Moodie P
N Z Med J; 2005 Feb; 119(1229):U1871. PubMed ID: 16498471
[No Abstract] [Full Text] [Related]
15. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
16. [A drug seeks its disease].
Löfgren O
Lakartidningen; 2010 Jun 2-8; 107(22):1488-9. PubMed ID: 20645604
[No Abstract] [Full Text] [Related]
17. Patients with overactive bladders deserve better.
Brenner B; Rice M
N Z Med J; 2006 Feb; 119(1229):U1846. PubMed ID: 16498474
[TBL] [Abstract][Full Text] [Related]
18. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
Athanasopoulos AA; Perimenis PS
BJU Int; 2005 May; 95(7):1117-8. PubMed ID: 15839945
[No Abstract] [Full Text] [Related]
19. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
Chapple CR; Martinez-Garcia R; Selvaggi L; Toozs-Hobson P; Warnack W; Drogendijk T; Wright DM; Bolodeoku J;
Eur Urol; 2005 Sep; 48(3):464-70. PubMed ID: 15990220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
